Status note Lead product candidate. Pre-IND briefing package and meeting request submitted Jun 4, 2024; pre-IND meeting with FDA held Sep 2024 to align on the 505(b)(2) regulatory pathway. Studies required to support an IND submission completed; advancing toward human clinical trials.
SPU-16
Stage not disclosed · TerminatedModality: central nervous system-homing peptides
Partnerships University of Maryland, Baltimore: Master License Agreement (Feb 12, 2021) terminated Jul 8, 2025; subsequent exclusive option to negotiate a new commercial license expired unexercised on Mar 31, 2026
Indications
Multiple sclerosis(Stage not disclosed)
Other neuroinflammatory pathology(Stage not disclosed)
Status note UMB license terminated Jul 8, 2025 and the option to negotiate a new license expired unexercised Mar 31, 2026; Silo no longer holds rights to this asset.
SP-26
Stage not disclosed · Active
Indications
Chronic pain, including fibromyalgia(Stage not disclosed)
Status note Provisional patent application filed Mar 2023; intended for development under the FDA 505(b)(2) regulatory pathway for repurposed drugs.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.